# Phase 1/2 Carcinoma, Hepatocellular trials: 52 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 52 trials in phase 1/2 for Carcinoma, Hepatocellular that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Carcinoma, Hepatocellular trials: 52 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/carcinoma-hepatocellular

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 52
- Recruiting or not yet: 52
- Read on: November 19, 2026

## Trials

The 25 newest of 52, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 16, 2026 | NCT07878689 | Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma | University of Texas Southwestern Medical Center | Phase 1/2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878689) |
| August 12, 2026 | NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | HCC - Hepatocellular Carcinoma | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761286) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| July 20, 2026 | NCT07714317 | Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in... | Shanghai Zhongshan Hospital | Phase 1/2 | Not yet recruiting | Resectable Hepatocellular Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714317) |
| July 15, 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer... | 770 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705074) |
| June 9, 2026 | NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors | VM Discovery, Inc. | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer... | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636785) |
| May 15, 2026 | NCT07590336 | 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma | Peking Union Medical College Hospital | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590336) |
| April 23, 2026 | NCT07547553 | A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC | Huahui Health | Phase 1/2 | Recruiting | Advanced or Unresectable Hepatocellular Carcinoma (HCC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07547553) |
| April 13, 2026 | NCT07523529 | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Unresectable, Metastatic | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523529) |
| April 13, 2026 | NCT07522411 | Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence... | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Hepatocellular Carcinoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07522411) |
| March 27, 2026 | NCT07495215 | A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in... | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07495215) |
| March 18, 2026 | NCT07479485 | MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) | Lepu Biopharma Co., Ltd. | Phase 1/2 | Recruiting | Hepatocellular Carcinoma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07479485) |
| February 13, 2026 | NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410494) |
| December 18, 2025 | NCT07291076 | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line... | Bristol-Myers Squibb | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC) | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07291076) |
| December 15, 2025 | NCT07282184 | Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention | Tongji Hospital | Phase 1/2 | Recruiting | Hepotacellular Carcinoma | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282184) |
| November 12, 2025 | NCT07227012 | Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult... | Pfizer | Phase 1/2 | Recruiting | Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma... | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227012) |
| September 22, 2025 | NCT07187284 | EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor... | Zhongda Hospital | Phase 1/2 | Not yet recruiting | HCC - Hepatocellular Carcinoma | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07187284) |
| July 20, 2025 | NCT07075419 | JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure | West China Hospital | Phase 1/2 | Not yet recruiting | Refractory Hepatocellular Carcinoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07075419) |
| July 17, 2025 | NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | GV20 Therapeutics | Phase 1/2 | Recruiting | Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS... | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070518) |
| June 29, 2025 | NCT07042919 | Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular... | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07042919) |
| April 4, 2025 | NCT06911255 | Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06911255) |
| February 6, 2025 | NCT06811116 | Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell... | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8... | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06811116) |
| January 27, 2025 | NCT06795022 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | AstraZeneca | Phase 1/2 | Recruiting | Hepatocellular Carcinoma | 304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06795022) |
| December 18, 2024 | NCT06741020 | Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma | Zhejiang Cancer Hospital | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06741020) |
| December 10, 2024 | NCT06726161 | Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3)... | RayzeBio, Inc. | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC) | 590 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06726161) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Eureka Therapeutics Inc. | 2 |
| Mayo Clinic | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| Parabilis Medicines, Inc. | 1 |
| University of Alabama at Birmingham | 1 |
| Twinpig Biolab, Inc. | 1 |
| Shanghai Public Health Clinical Center | 1 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| Arvinas Inc. | 1 |
| University of Texas Southwestern Medical Center | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 1 |
| VM Discovery, Inc. | 1 |
| National Cancer Institute (NCI) | 1 |
| Essen Biotech | 1 |
| Zhongda Hospital | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |
| Rznomics, Inc. | 1 |
| Lepu Biopharma Co., Ltd. | 1 |
| Chinese PLA General Hospital | 1 |
| GI Innovation, Inc. | 1 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 1 |
| Children's Oncology Group | 1 |
| St. Jude Children's Research Hospital | 1 |
| GV20 Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 26 |
| China | 22 |
| Taiwan | 7 |
| South Korea | 6 |
| Japan | 5 |
| Australia | 4 |
| France | 3 |
| Italy | 3 |
| Spain | 3 |
| Puerto Rico | 2 |
| Chile | 2 |
| Germany | 2 |
| Poland | 2 |
| Brazil | 2 |
| Singapore | 1 |
| United Kingdom | 1 |
| Hong Kong | 1 |
| New Zealand | 1 |
| Switzerland | 1 |
| Canada | 1 |
| Argentina | 1 |
| Belgium | 1 |
| Ireland | 1 |
| Mexico | 1 |
| Netherlands | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Logging contractors in the United States](https://specstream.ai/data/businesses/logging-contractors/united-states)
- [Asian fusion restaurants in the United States](https://specstream.ai/data/businesses/asian-fusion-restaurants/united-states)
- [Irrigation contractors in the United States](https://specstream.ai/data/businesses/irrigation-contractors/united-states)
- [Workers compensation law firms in the United States](https://specstream.ai/data/businesses/workers-compensation-law-firms/united-states)
- [Hot dog restaurants in the United States](https://specstream.ai/data/businesses/hot-dog-restaurants/united-states)
- [Vehicle manufacturers in the United States](https://specstream.ai/data/businesses/vehicle-manufacturers/united-states)
